ArticleMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2025
Radiomic Analysis Applied to Pretreatment Gd-EOB-DTPA-enhanced MR Imaging Predicts Response to Selective Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Article in Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and LI-RADS features on gadoxetic acid‑enhanced MRI for predicting complete response after transarterial chemoembolization in hepatocellular carcinoma > 2 cm.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of radiomic analysis applied to pretreatment gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI (Gd-EOB-DTPA-MRI) for predicting the response to transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma.
methodsData and images from 40 consecutive patients (28 men, 12 women) who underwent pretreatment Gd-EOB-DTPA-MRI and a total of 52 TACE procedures for 75 non-treated hepatocellular carcinomas were retrospectively analyzed. Two radiologists manually outlined lesions on pretreatment arterial- and hepatobiliary-phase hepatic images to extract radiomic features. The radiomics data from one observer were randomly divided into a training dataset and a validation dataset in the ratio of 7:3. Radiomic features extracted using least absolute shrinkage and selection operator (LASSO) binomial regression applied to the training dataset and that showed intraclass correlation coefficients (ICC) >0.7 were used to construct a radiomic model. The predictive performance of the model was evaluated using receiver operating characteristics curves. Lesions classified as showing a complete or partial response according to the modified RECIST criteria were allocated to a response group.
resultsThere was no significant difference in Child-Pugh score, tumor marker values, or TACE procedure between response and non-response groups. Six radiomic features were selected using the LASSO binomial regression and 5 of them showing an ICC >0.7 were used to establish the radiomic model. The area under the curve of the radiomic model was 0.89 for the training dataset, 0.83 for the validation dataset, and 0.83 for the other observer's data. The sensitivity and specificity for the prediction of tumor response to TACE were 78% and 92% for the training dataset; 71% and 50% for the validation dataset; and 75% and 79% for the other observer's data.
conclusionThe pretreatment Gd-EOB-DTPA-MRI-based radiomic model is useful for predicting the response to TACE of hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.